As DFS time is a valuable parameter in evaluating patients’ health status after surgery and the impact of FGFR1 amplification to DFS and OS showed a delayed trend, so we divided the whole cohort of ESCC patients into two groups according to different DFS times (24, 26, 28, 30, and 32 month respectively). This evidence concerns the gene FGFR1 and esophageal squamous cell carcinoma.